Navigation Links
QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
Date:10/25/2012

HILDEN, Germany, October 25, 2012 /PRNewswire/ --

  • QIAGEN and Bayer HealthCare signed collaboration agreement aimed at advancing both companies positions in personalized medicine
  • The programs pair QIAGEN companion diagnostic solutions with innovative targeted therapies for patients with solid tumors developed by Bayer HealthCare
  • Agreement provides framework for further collaboration projects

QIAGEN (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) and Bayer HealthCare today announced a collaboration agreement for the development and commercialization of companion diagnostics paired with novel Bayer HealthCare drugs, initially to enhance the treatment of various solid tumors. Companion diagnostics are tests that unlock molecular information from each patient's tumor genome to guide treatment decisions with medications for cancers or other diseases. The parties will also collaborate on the development of novel technologies for patient profiling which may result in innovative research-use-only products for exploratory and translational medicine. Financial details were not disclosed.

The targeted companion diagnostics will be designed to run on the QIAsymphony family of automated instruments, which is transforming laboratory workflows and helping disseminate standardized, regulator-approved diagnostics.

"We are very pleased to partner with Bayer HealthCare in developing companion diagnostics to improve life for cancer patients. As healthcare providers increasingly select the right drugs based on each individual's genomic information, the treatment of cancer is undergoing a revolution," said Dr. Helge Lubenow, Senior Vice President Molecular Diagnostics Business Area and Member of the Executive Committee of QIAGEN. "The first collaborations for Bayer HealthCare and QIAGEN include companion diagnostics ba
'/>"/>

SOURCE Qiagen N V
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. QIAGEN Acquires AmniSure International to Add Unique Assay to Emerging Point of Need Portfolio
2. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
3. BioHealth Innovation, Inc. Appoints Qiagens Douglas Liu to Board of Directors
4. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
5. QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
6. Bayer Advanced(TM) Sets Sights on New Partnerships in 2013
7. Bayer HealthCares Cotavance® Drug Eluting Balloon With Paccocath® Technology Reduced Five-Year Target Lesion Revascularization Rates by 59 Percent in PAD Patients Compared to Those Treated With Uncoated Balloon
8. AspenBio to Present at 2012 Aegis Healthcare Conference
9. Neuralstem President And CEO To Present At The 2012 Rodman & Renshaw Annual Healthcare Conference
10. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
11. AtheroNova to Present at Rodman & Renshaw 14th Annual Healthcare Conference in New York City
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... May 21, 2015  Susan Hedstrom, Executive Director ... nonprofit organization dedicated to supporting research to advance ... announced today that FPWR has received the organization,s ... Shaulov contributed $1 million in support of ... "Our gift signifies ...
(Date:5/21/2015)... May 21, 2015 W. R. ... manufacturing facility in Worms, Germany has received good ... subsidiary of the International Pharmaceutical Excipient Council (IPEC) ... that produce its SYLOID® FP brand of pharmaceutical ... certification, following the Curtis Bay, Maryland (USA) and ...
(Date:5/21/2015)... 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (TSX.V: ... company focused on the development of autologous cell ... the International Society for Cellular Therapy (ISCT) on ... currently in a Phase 1/2 clinical trial.  The ... from 5:30 PM to 7:00 PM local time, ...
(Date:5/20/2015)... MA (PRWEB) May 20, 2015 This ... history, especially for lawns. US Patented Pearl’s Premium ... for lawns around the country that are coming out ... that addresses a number of major global concerns related ... the “non-grass” grass – the alternative to the standard, ...
Breaking Biology Technology:The Foundation for Prader-Willi Research Receives $1M Contribution in Support of Clinical Initiatives 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Breakthrough 4th Generation Low Maintenance Lawn Seed Offers Solution to California Drought 2
... familiar with these three words, after all that has happened ... shown the importance of being current with ones network security ... attacks came via the blaster worm, which took advantage of ... Following closely on its heels were Sobig, Nacha, and ...
... bread and butter of Wisconsins economic growth will be ... to transfer our best technology to the marketplace, controlling ... ensuring theres a 21st century infrastructure in place to ... to the equation, too, that may prove as vital ...
... WI- Frost & Sullivan has announced that Camtronics ... Corporation as the recipient of both the 2003 ... information management market and the 2003 Market Penetration Leadership ... , ,Outstanding achievements in these areas have helped ...
Cached Biology Technology:Athletics, pop culture and the arts 2Athletics, pop culture and the arts 3Camtronics Receives Health IT Awards 2
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/11/2015)... 11, 2015 Curemark LLC, a privately held ... a new Phase III double blind, randomized, placebo-controlled clinical ... CM-AT, on all children ages 3-8 with Autism. Previously, ... III double blinded clinical trial for CM-AT in children ... the digestive enzyme chymotrypsin. This new trial will help ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... making the public aware of the stark difference between ... from Professor Barry Brook, Director of the Research Institute ... Adelaide, Australia. In an opinion piece published today ... has urged scientists to stand up to those who ...
... press release is not and,must not be, directly or ... Africa or the United States of America. The,Offer is ... elsewhere,where their participation requires further offer documents, filings or,other ... This is a,translation of the original Swedish language press ...
... a leading supplier of broadband technology and biometrics software,has ... results,for the first quarter of 2008 on Thursday, May ... and CFO Rick Moberg will host the,earnings conference call., ... can be accessed on the,Investor Relations page of our ...
Cached Biology News:Scientists urged to make a stand on climate change 2Oberthur Technologies XPon Offer 2Aware Announces Q1 2008 Earnings Conference Call 2
... delivers enhanced statistics and statistical interpretation ... improvement managers. As an accepted organizational ... simplifies statistics for novice users and ... experts. It offers a powerful JMP ...
... Choice Microsphere/Microarray Stabilizer is a is a ... This product is an aqueous solution ... buffer (phosphate buffered saline), pH 6.6 - ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane as ...
... Microarray plates are ideal for use as source ... handling applications (down to 5µl). These plates are ... design. Features 384 round ... 70µl well volume (cylindrical well), 55µl well ...
... is an aqueous-based mounting medium designed ... sections. Gel/Mount is especially recommended when ... or FluoroBlue. It can also be ... as fluorescein (FITC), Rhodamine (TMRITC) and ...
Biology Products: